Breaking News, Financial News

2Q Financial Report: Johnson & Johnson

Johnson & Johnson
 
2Q Revenues: $13.4 billion (+5%)

2Q Earnings: $2.8 billion (+7%)

YTD Revenues: $26.4 billion (+3%)

YTD Earnings: $6.1 billion (+13%)

Comments: Worldwide pharmaceutical sales were $5.8 billion for the quarter, up 3.2%. Sales growth for the quarter was driven by Risperdal, Remicade, Topamax, and Concerta. During the quarter, the FDA approved Ionsys, the first needle-free, patient-activated analgesic system and Remicade for reducing signs and symptoms in pediatric patients with moderately to severely active Crohn’s disease.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters